SRPT

Sarepta Therapeutics,, Inc. Common Stock

$17.61 -1.45%

Recent alerts on SRPT

All signals →

News Stock Market Today: Dow Futures Gain, S&P 500 Slips As Investors Brace For Mega-Cap Earnings— Brand Engagement, Nucor In Focus (UPDATED)

News Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?

News AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?

News Stocks Slip As Netflix Fails To Impress, Bitcoin Eyes Negative Week: What's Moving Markets Friday?

News Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

News Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

News Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday?

News Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

News Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday

News Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod

News FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

News Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says

News Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?

News Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

News Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year

News Implied Volatility Surging for Sarepta (SRPT) Stock Options

News Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months

News 12 Analysts Have This To Say About Sarepta Therapeutics

News Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

News Sarepta reiterates $1.2B-$1.4B 2026 net product revenue guidance while targeting Cohort 8 data by year-end

News Sarepta turns negative despite Q1 beats; 2026 guidance maintained

Short interest Short interest 24.1% of float

News Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod

Insider trade Sale by Stephen Mayo

News Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Get push alerts for SRPT

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS